Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.

CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operational execution. The Company believes that, without adequate working capital, scaled sales, and a sustained product launch into the market, the risks of competitive lag increase, the capacity to convert research into recurring revenue is constrained, and the organization becomes exposed to operational frictions that may affect continuity and growth.

If completed, the proceeds would be used primarily to enable and execute an integrated plan that includes, among other corporate purposes: (i) the commercial launch and expansion of CBIH's product portfolio—including VitaCookies, ointments, tinctures, and capsules; (ii) strategic costs associated with the protection, maintenance, and defense of the Company's intellectual property and patent portfolio; and (iii) the costs to establish, deploy, and scale CBIH's statewide educational programs, including the infrastructure and execution required for implementation.

In parallel, CBIH continues to execute an agenda of alliances and coordination with ecosystem participants including technical teams, healthcare organizations, and institutional counterparties with the objective of converting interest into verifiable work plans, strengthening operational capabilities, compliance, and quality standards oriented toward results.

"This evaluation is not about headlines; it is about execution discipline and the protection of corporate value," said Rebeka Lopez, CPA, Director of Finance at CBIH. "Our objective is to enable working capital to bring products to market in an orderly manner, sustain appropriate sales, and support the defense of our intellectual property assets and educational programs with a serious business-focused approach."

With respect to financing, CBIH stated that its approach is to structure any alternative with compliance standards and prudent communications. At this stage, the Company is reviewing scenarios, costs, and operational priorities, as well as the optimal sequencing for execution and disclosure, seeking consistency with its public reporting obligations.

CBIH emphasizes that, as of the date hereof, there is no certainty that an offering will be pursued, nor as to the final terms, timing, structure, or definitive amount, and any decision will be subject to additional internal evaluations, professional advice, and the applicable regulatory framework.

CBIH believes that this evaluation stage represents a reasonable and strategic opportunity to convert years of medical research, medicinal formulation development, and intellectual asset building into tangible and sustainable outcomes. For nearly two decades, the Company has invested work and capital in applied science, intellectual property, and education, including audiobooks, electronic books, and educational videos, with the purpose of elevating standards for the responsible, evidence-based use of cannabinoid-derived therapies.

In this context, CBIH views the current environment, driven by the federal rescheduling of cannabis, as an inflection point that enables the Company to execute a comprehensive commercial and educational plan with greater clarity, rigor, and reach. The Company intends to capitalize on this moment with discipline and determination by accelerating the launch of its portfolio and consolidating its strategic programs, with the expectation that this step will contribute to realizing, finally, the value that corresponds to many years of serious and consistent work.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at .

To view the source version of this press release, please visit